Corner Therapeutics raised $54 million in a Series A funding led by Ziff Capital Partners to create vaccines that confer lifelong protection from cancer and infectious diseases.
Sandia HoldingsTanis VenturesCockrell InterestsZiff Capital Partners
Description
US immune therapies and vaccines developer Corner Therapeutics has raised $54 million in a Series A funding to create vaccines that confer lifelong protection from cancer and infectious diseases.
Company Information
Company
Corner Therapeutics
Location
498 N Beacon St
Watertown, Massachusetts, United States
About
Corner is pioneering a new class of immunotherapies. Our versatile dendritic cell hyperactivation (hDC) platform is unique in its ability to address a virtually unbounded range of cancers and infectious diseases. Our platform technology induces exceptional memory T cell responses that provide robust and durable immunity. Corner seeks to transform standard of care, ushering in a new era of robust, rapid, patient-friendly and low-cost immunotherapies – even for the most difficult to treat diseases.
Fundz sees it the moment Corner Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyHealth CareTherapeuticsresearch